CN101028246A - Anti-cancer composition containing neoformative vascular inhibitor and hormone medicine - Google Patents

Abstract

An anticancer composition containing neovascular inhibitor and hormone medicine and able to be made into slow-release implant or injection is composed of the slow-release microballs and solvent. Said slow-release microball consists of active anticancer component (neovascular inhibitor and/or hormone medicine) and slow-release additives (p (LAEG-EOP), p (DAPG-EOP), etc). Said solvent is an ordinary solvent or the special solvent containing the suspending aid.

Description

A kind of anti-cancer composition that contains neovascularization inhibitor and hormone medicine

(1) technical field

The present invention relates to a kind of anti-cancer composition that contains neovascularization inhibitor and/or hormone medicine,, belong to technical field of pharmaceuticals for slow-releasing anticarcinogen injection and sustained-release implant.

(2) background technology

As class chemotherapeutics commonly used, neovascularization inhibitor has been widely used in the treatment of multiple malignant tumor, and action effect is comparatively obvious.Yet its significant toxic reaction has greatly limited the extensive use of such medicine.

Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, and therefore, conventional chemotherapy is difficult to tumor by local and forms effective drug level.In addition, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fibrin and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).So, improve the restriction that dosage is subjected to general reaction again merely.Pharmaceutical topical application may solve the problem of drug level to a certain extent, yet operation techniques such as medicine implantation are complicated, traumatic big, the various complication such as, infection hemorrhage, immunity reduction, also can cause or quicken the diffusion and the transfer of tumor except that easily causing.In addition, the preparation of perioperatively itself and expensive expense usually influence its effective enforcement.

In addition, the DNA repair function in many tumor cells obviously increases after chemotherapy.The latter often causes the enhancing of tumor cell to the toleration of cancer therapy drug, consequently treatment failure.In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth " (referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., Int J Cancer.2004; 111 (4): 484-93)).

Therefore, study both handled easilies, can keep high drug level at tumor by local can increase tumor cell again the preparation of the sensitivity of medicine and method are just become when previous important topic.

(3) summary of the invention

The present invention is directed to the deficiencies in the prior art, a kind of anticancer pharmaceutical composition that contains neovascularization inhibitor (Ai) and hormone medicine is provided, particularly, is a kind of slow-releasing anticarcinogen injection or sustained-release implant that contains neovascularization inhibitor and hormone medicine

Neovascularization inhibitor has been widely used in the multiple entity tumor of treatment both at home and abroad as the new cancer therapy drug of a class.Yet in application process, its tangible general toxicity has greatly limited the application of this medicine.

The present invention finds that hormone medicine and neovascularization inhibitor share its antitumaous effect is strengthened mutually; In addition, the combination of neovascularization inhibitor and hormone medicine is made drug level that anticancer medicine slow-release preparation containing (being mainly slow releasing injection and sustained-release implant) not only can greatly improve tumor by local, reduces the drug level of medicine in blood circulation, is reduced the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The above unexpected main contents of the present invention of finding to constitute.

The present invention also finds, with regard to composition such as neovascularization inhibitor and hormone medicine with active anticancer, is not the slow release effect that all slow-release auxiliary material all can reach effective release.Pharmaceutic adjuvant have hundreds of more than, pharmaceutic adjuvant with slow releasing function, particularly the pharmaceutic adjuvant that different pharmaceutical slowly can be discharged in the regular hour in human body or animal body must could obtain through a large amount of creationary experiments, specific slow-release auxiliary material and can need be passed through a large amount of creative works by the selection of the combination of slow releasing pharmaceutical and could determine.Discharged and be not enough to obtain active drug concentration slowly, thereby effective tumor killing cell; Cause prominent releasing if discharge too fast meeting, then cause the whole province's toxic reaction easily, as polifeprosan (A.J.Domb etc., Biomaterials (1995), 16 (14): 1069-1072; Wenbin Dang etc., Journal of Controlled Release (1996), 42:83-92; Eric P.Sipos etc., Cancer Chemother Pharmacol (1997), 39:383-389; Lawrence K.Fung etc., Cancer Research (1998), 58:672-684).The data of release characteristics need could obtain through a large amount of creationary experiments in inside and outside in the related data, particularly animal body, are not just can determine to have unobviousness through limited experiment.

The present invention finds, poly-phosphide (polyphosphoesters), poly phosphate (polyphosphate), poly-phosphite ester (polyphosphite), polyphosphonates (polyphosphonate), polyester cyclic phosphate (poly (cycloaliphatic phosphoester)), etherophosphoric acid phosphate ester high molecular polymers such as (EOP) can steadily slowly discharge effective ingredient of the present invention, and deenergized period is more than 40 to 100 days.And do not have prominent releasing, particularly mix or copolymerization with sugared acid anhydride family macromolecule such as polylactic acid.The prominent deficiency of releasing with too fast release of more than finding to have solved existing slow releasing preparation is slowly more than release 40-100 days.More than find to constitute principal character of the present invention.

Neovascularization inhibitor of the present invention is a slow releasing agent, and anticancer anticancer sustained-release agent is mainly slow releasing injection or sustained-release implant.

A kind of form of the present invention is a slow releasing injection, is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:

(A) sustained-release micro-spheres comprises:

Anticancer effective component 0.5-70%

Slow-release auxiliary material 30-99%

Suspending agent 0.0-30%

More than be weight percentage

With

(B) solvent is for common solvent or contain the special solvent of suspending agent.

Wherein,

Anticancer effective component is neovascularization inhibitor and/or hormone medicine.

Vasoinhibitor is selected from one of following or combination: ZD6474, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin, TNP-470.

Above vasoinhibitor also comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate and maleate etc.

Above-mentioned neovascularization inhibitor shared ratio in slow releasing agent is decided because of concrete condition, can be 0.01%-50%, is good with 0.1%-40%, and 1%-30% is best.Below all be weight percentage.

Steroids anti-cancer drugs is mainly steroid hormone and hormone antagonist, comprise, but be not limited to, triptorelin, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane, bicalutamide

Above steroids anti-cancer drugs can be used for the tumor that various hormones rely on, but different pharmaceutical has relative tumor-selective, as, tamoxifen, (.+-.)-Pyridoglutethimide, rubitecan, Acapodene etc. mainly rely on estrogenic tumor in order to treatment, as breast carcinoma and carcinoma of endometrium; Drogenil, overstate that single silicon indigo plant and bicalutamide mainly rely on androgenic tumor in order to treatment, as carcinoma of prostate; Triptorelin, goserelin, leuprorelin, tamoxifen, raloxifene, aminoglutethimide, clomifene, toremifene, letrozole, Anastrozole and exemestane are then in order to treatment breast carcinoma, carcinoma of prostate and carcinoma of endometrium.

The content of steroids anti-cancer drugs in compositions is 0.01%-60%, is good with 1%-40%, is best with 5%-30%, more than all be weight percentage.

The percentage by weight of antitumor drug in medicament slow-release microsphere is 0.5%-60%, is good with 2%-40%, is best with 5%-30%.When use in conjunction, the weight ratio of neovascularization inhibitor and hormone medicine is 1-9: 1 to 1: 1-9, with 1-4: 1 and 4-1: 1 serves as preferred, 1-2: 1 and 2-1: 1 for most preferably.

Anticancer effective component in the slow-releasing anticarcinogen injection microsphere of the present invention is preferably as follows, and all is weight percentage:

(a) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin or TNP-470;

(b) triptorelin of 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane or bicalutamide; Or

(c) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin, the triptorelin of TNP-470 and 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, the 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, the combination of exemestane or bicalutamide.

Slow-release auxiliary material range of viscosities IV (dl/g) 0.05～1.8 serves as preferred with 0.1～1.4, with 0.1～1.4 for most preferably.The used slow-release auxiliary material of the present invention is selected from poly-phosphide (polyphosphoesters), poly phosphate (polyphosphate), poly-phosphite ester (polyphosphite), polyphosphonates (polyphosphonate), polyester cyclic phosphate (poly (cycloaliphatic phosphoester)), etherophosphoric acid (EOP), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester, 80/20) (p (BHET-EOP/TC, 80/20)), p (BHET-EOP/TC, 50/50), poly-(L-lactide-co-etherophosphoric acid (p (LAEG-EOP)), poly-(L-lactide-co phosphoric acid propyl ester) (p (DAPG-EOP)), anti-(formula)-1,4-dimethyl cyclohexane (trans-1,4-cyclohexanedimethanil, CHDM), hexyl dichloro-phosphate ester (hexyl phosphorodichloridate, HOP), 4-dimethylamino pyridine (4-dimethylaminopyridine, DMAP), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride, 80/20) (p (BHDPT-EOP/TC, 80/20)), p (BHDPT-EOP/TC, 50/50), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) (p (CHDM-HOP)), poly-(anti-(formula)-1, a kind of or its combination in the 4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)).

Serve as preferred with p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP), p (CHDM-EOP) in the above-mentioned phosphate ester.

The used slow-release auxiliary material of the present invention also is selected from above-mentioned phosphate ester and poly-dl-lactide (D, L-PLA), poly-dl-lactide/ethanol copolymer (D, L-PLGA), monomethyl polyethylene glycol (MPEG-PLA), monomethyl polyethylene glycol copolymer (MPEG-PLGA), polyethylene glycol (PLA-PEG-PLA), polyethylene glycol copolymer (PLGA-PEG-PLGA), end carboxyl polylactic acid (PLA-COOH), end carboxyl polylactic acid/ethanol copolymer (PLGA-COOH), polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), PPDO (PDO), PTMC (PTMC), xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer 188, poloxamer 407, hyaluronic acid, collagen protein, the blend of gelatin or albumin glue or copolymer.Wherein the shared percentage by weight of phosphate ester is 1-99%, is preferred with 40-80%, and 50-60% is for most preferably.

The used slow-release auxiliary material of the present invention also is selected from the combination of the copolymer (PLGA) of polifeprosan and polylactic acid (PLA) or polyglycolic acid and hydroxyacetic acid.

The used slow-release auxiliary material of the present invention also is selected from the combination of organosilicon or itself and above-mentioned adjuvant, and organosilicon can be used as the centre of sphere of microsphere or as the carrier of microsphere.

Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.

For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.

Except that above-mentioned adjuvant, also can select for use other materials to see United States Patent (USP) (4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.

The content of suspending agent is decided because of the medicine that solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule), the preparation method of injection and the kind and the composition thereof of suspending agent, as, sodium carboxymethyl cellulose can be 0.5-5%, but with 1-3% is preferred, mannitol and/or sorbitol are 5-30%, but is preferred with 10-20%, and polysorbas20, polysorbate40 or Tween 80 are 0.05-2%, but are preferred with 0.10-0.5%.In most cases, sustained-release microparticle is made up of effective ingredient and slow-release auxiliary material, and solvent is special solvent.When solvent was common solvent, medicine that is suspended or sustained-release micro-spheres (or microcapsule) then were made up of effective ingredient, slow-release auxiliary material and/or suspending agent.In other words, when the suspending agent in the sustained-release microparticle (A) was " 0 ", solvent (B) was special solvent, and when the suspending agent in the sustained-release microparticle (A) was not " 0 ", solvent (B) can be common solvent or special solvent.The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).

Common solvent can be, but is not limited to, the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt, and pharmacopeia has respective specified; The special solvent of indication of the present invention is the common solvent that contains suspending agent, suspending agent can be, but be not limited to one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, polysorbas20, polysorbate40 and Tween 80 or its combination.The content of suspending agent is 0.1-30% volume weight percentage ratio in the special solvent, is preferably as follows:

(a) 0.5-5% sodium carboxymethyl cellulose; Or

(b) 0.5-5% sodium carboxymethyl cellulose and 0.1-0.5% Tween 80; Or

(c) 5-20% mannitol; Or

(d) 5-20% mannitol and 0.1-0.5% Tween 80; Or.

(e) 0.5-5% sodium carboxymethyl cellulose, 5-20% sorbitol and 0.1-0.5% Tween 80.

The above-mentioned volume weight percentage ratio that is contains the weight of suspending agent in the common solvent of unit volume, as g/ml, kg/L down with

The preparation of injection comprises that the preparation of preparation, solvent of sustained-release micro-spheres or drug microparticles and sustained-release micro-spheres or drug microparticles suspend, and make injection at last in solvent.

Wherein, sustained-release micro-spheres or drug microparticles can prepare with some kinds of methods: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are in conjunction with freezing (drying) comminuting method, liposome bag medicine method and emulsion process etc.Serve as preferred wherein with dissolution method (being the solvent volatility process), freezing (drying) comminuting method, seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection.The particle diameter of suspended drug or sustained-release micro-spheres (or microcapsule) decide because of specifically needing, and can be, but be not limited to, 1-300um, but be that preferably 30-150um most preferably with 20-200um.Medicine or sustained-release micro-spheres can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller.Slow-release auxiliary material is above-mentioned bio-capacitivity, biodegradable or non-biodegradation polymer.

The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or Tween 80 (0.1%) are dissolved in the normal saline mutually deserved solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).

The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).

The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.

The application of injection comprises the application of the injection of making after the application of application, solvent of sustained-release micro-spheres or drug microparticles and sustained-release micro-spheres or drug microparticles suspend in solvent.

Microsphere is used to prepare slow releasing injection, as suspension type slow releasing injection, gel injection, block copolymer micelle injection.In various injections, serve as preferred with the suspension type slow releasing injection.The suspension type slow releasing injection is to contain the medicament slow-release microsphere of effective composition or the preparation that drug microparticles is suspended in gained in the solvent, and used adjuvant is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt; Block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be at 1-300um, but is preferred with 20-200um, and 30-150um most preferably; Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.

The application of solvent refers to that mainly the application of special solvent is effective suspension, stablizes and/or protects various medicines or sustained-release micro-spheres (or microcapsule), thereby prepares corresponding injection.The application of special solvent can make prepared injection have better injectivity, stability and higher viscosity.

The application of injection be with full-bodied special solvent with pastille microgranule, particularly sustained-release microparticle, make corresponding slow releasing injection, thus make corresponding medicine can with the injection mode import in the patient or mammalian body of required medicine.The medicine that is injected can be, but is not limited to, said medicine micropowder or medicament slow release microgranule.

The route of administration of injection depends on multiple factor.For the non-proliferative pathological changes, can be in vein, lymphatic vessel, subcutaneous, muscle, intracavity (in as abdominal cavity, thoracic cavity, articular cavity and in the canalis spinalis), tissue, tumor in, reach in the bone marrow in all, the selective arterial injection of tumor, lymph node and inject.For proliferative lesion, as the entity tumor, though can be through above-mentioned administration, with in selective arterial, intracavity, the tumor, the injection of tumor week serves as preferred.

For obtaining valid density in former or position, metastatic tumour place, also can unite and give through number of ways, in the time of as vein, lymphatic vessel, subcutaneous, muscle, intracavity (as in abdominal cavity, thoracic cavity, the articular cavity and in the canalis spinalis) or selective arterial injection in conjunction with local injection.So administering drug combinations is specially adapted to entity tumor.As in the tumor, tumor week injection time is in conjunction with systemic injection.

The present invention can be used to prepare the medicine of the various tumors for the treatment of people and animal, is mainly slow releasing injection.

Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.

The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.

The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.

The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.

The route of administration of slow releasing agent depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.

The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.

The tumor of above-mentioned internal organs can be different histological type, and why the tumor of the lymph node of lymph node divides outstanding golden lymphoma and non_hodgkin lymphoma, and pulmonary carcinoma comprises small cell lung cancer and nonsmall-cell lung cancer etc., and the cerebral tumor comprises glioma etc.Yet common tumor comprises entity tumors such as the retinoblastoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis of the cerebral tumor, cerebral glioma, renal carcinoma, hepatocarcinoma, carcinoma of gallbladder, tumor of head and neck, oral cancer, thyroid carcinoma, skin carcinoma, hemangioma, osteosarcoma, lymphoma, pulmonary carcinoma, thymic carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, eyes.

The application of sustained-release implant and the same slow-releasing anticarcinogen injection of potentiation mode, the cancer therapy drug that place the associating of the chemical-therapy synergistic agent of the associating of the cancer therapy drug of the promptly local chemical-therapy synergistic agent of placing and other administration, the local cancer therapy drug of placing and other administration, part and the associating of the local chemical-therapy synergistic agent of placing.Wherein the cancer therapy drug of topical application and chemical-therapy synergistic agent can be separately or Joint Production, packing, sale, use.Packing refers to medicine carrying process and pastille slow-release agent the exterior and interior packing for transport and/or store of medicine for adjuvant.The medicine carrying process includes, but not limited to weighing, dissolving, mixing, drying, shaping, coating, spraying, granulation etc.As medicine is mixed and made into the sustained-release micro-spheres that contains different pharmaceutical with different adjuvant, this sustained-release micro-spheres is packing and storing separately, when using simultaneously or successively be injected in the body; This sustained-release micro-spheres also can further be shaped by several different methods, makes the sustained-release implant of different shape.

The clinical practice dosage of effective ingredient depends on patient's concrete condition, can be from 0.01 to 1000mg/kg body weight, and 0.1 to 800mg/kg is preferred, 1 to 500mg/kg for there being most choosing.

The consumption of the anticancer effective component in the sustained-release implant can be with reference to slow releasing injection.But be preferably as follows:

The ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, the triptorelin of Amebacilin or TNP-470 and 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, the 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, the combination of exemestane or bicalutamide.

Also can add other medicinal ingredient in the made slow releasing injection of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.

By following test and embodiment technical method of the present invention is further described:

Local drug concentration after test 1, different modes application response stop relatively

With the rat is subjects, with 2 * 10 ⁵Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 1 cm diameter its grouping.Every group of dosage is 5mg/kg.Measure medicament contg (%) in the different time tumor, the result shows, the local drug concentration significant difference of thalidomide after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.

The interior tumor-inhibiting action of body that test 2, different modes are used behind the ZD6474 compares

With the rat is subjects, with 2 * 10 ⁵Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats behind tumor growth to 0.5 cm diameter its grouping.Every group of dosage is 15mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 20th day.The result shows, the tumor-inhibiting action significant difference of ZD6474 after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.

The tumor-inhibiting action of test 3, Ai and hormone medicine

With the rat is subjects, with 2 * 10 ⁵Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-11).The treatment component is Ai, hormone medicine group, Ai and hormone medicine group.Ai group and hormone medicine drug dose are respectively 25mg/kg and 5mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 20th day.

Table 1

Group	Triptorelin	Ai	Tumor control rate (%)	The P value
					1	+	-	64	*
2	-	Erlotinib	46	*
					3	-	WAY-EKB 569	42	*
4	-	Thalidomide	38	*
					5	-	Angiostatin	48	*
6	-	The grace degree	36	*
					7	+	Erlotinib	86	**
8	+	WAY-EKB 569	82	**
					9	+	Thalidomide	88	**
10	+	Angiostatin	86	**
					11	+	The grace degree	82	**

Above result shows, neovascularization inhibitor (Ai) (Erlotinib, WAY-EKB 569, thalidomide, angiostatin, grace degree) and used hormone medicine (triptorelin) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.

The tumor-inhibiting action of test 4, gefitinib and hormone medicine (slow releasing injection)

Used tumor cell comprises CNS-1, C6, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT) etc.Gefitinib and hormone medicine are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect (%) and is shown in Table 2.

Table 2

Oncocyte	Ai	A	B	C	D	E	Ai+A	Ai+B	Ai+C	Ai+D	Ai+E
												CNS	52	50	48	38	58	42	88	88	82	78	88
C6	54	52	46	36	64	40	90	80	84	84	90
												SA	52	58	36	42	62	48	88	84	86	82	82
BC	58	54	40	42	64	54	88	80	74	74	80
												BA	68	46	38	48	60	56	80	80	92	92	80
LH	66	56	40	52	58	60	90	82	94	78	94
												PAT	60	48	46	50	54	68	82	76	82	80	80

Above result shows, used Ai (gefitinib) and hormone medicine (A wherein: Miproxifene, B: tamoxifen, C: not former times sweet smell, D: raloxifene, E: ICI-M 164384) growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.

The tumor-inhibiting action of test 5, rapamycin and hormone medicine (slow releasing injection)

Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Rapamycin and hormone medicine are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and shows, growth all has obvious suppression effect (P＜0.05) to kinds of tumor cells when using separately for used rapamycin and hormone medicine (anticancer steroid alkene phenol, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol), can show significant potentiation (P＜0.01) when use in conjunction.

Test 6, contain the tumor-inhibiting action of Ai and hormone medicine

With the rat is subjects, with 2 * 10 ⁵Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-11).The treatment component is Ai group, hormone medicine group, Ai and hormone medicine group.Ai group and hormone medicine drug dose are respectively 25mg/kg and 5mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 20th day.

Table 3

Group	Goserelin	AI	Tumor control rate (%)	The P value
					1	+	-	42	*
2	-	Lapatinib	46	*
					3	-	WAY-EKB 569	42	*
4	-	Thalidomide	38	*
					5	-	Angiostatin	48	*
6	-	The grace degree	36	*
					7	+	Lapatinib	78	**
8	+	WAY-EKB 569	72	**
					9	+	Thalidomide	78	**
10	+	Angiostatin	82	**
					11	+	The grace degree	80	**

Above result shows, Ai (WAY-EKB 569, thalidomide, angiostatin, grace degree) and used hormone medicine (goserelin) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.

The tumor-inhibiting action of test 7, Ai and hormone medicine (slow releasing injection)

Used tumor cell comprises CNS-1, C6, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT) etc.Neovascularization inhibitor and hormone medicine are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect (%) and is shown in Table 4.

Table 4

Oncocyte	Rapamycin	A	B	C	D	E	Rapamycin+A	Rapamycin+B	Rapamycin+C	Rapamycin+D	Rapamycin+E
												CNS	52	50	48	38	58	42	88	88	82	78	88
C6	54	52	46	36	64	40	90	80	84	84	90
												SA	52	58	36	42	62	48	88	84	86	82	82
BC	58	54	40	42	64	54	88	80	74	74	80
												BA	68	46	38	48	60	56	80	80	92	92	80
LH	66	56	40	52	58	60	90	82	94	78	94
												PAT	60	48	46	50	54	68	82	76	82	80	80

Above result shows that used hormone medicine is A: Miproxifene, B: tamoxifen, C: not former times sweet smell, D: raloxifene, E: ICI-M 164384.Growth all has the obvious suppression effect to said medicine to kinds of tumor cells when this concentration is used separately, can show significant potentiation when use in conjunction.

The tumor-inhibiting action of test 8, votaranib and hormone medicine (slow releasing injection)

Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Votaranib and hormone medicine are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its growth of tumour cell suppresses effect and shows, growth all has obvious suppression effect (P＜0.05) to kinds of tumor cells when using separately for used votaranib and hormone medicine (anticancer steroid alkene phenol, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol), can show significant potentiation (P＜0.01) when use in conjunction.

The tumor-inhibiting action of test 9, Ai and hormone medicine

With the rat is subjects, with 2 * 10 ⁵Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-9).The treatment component is Ai group, hormone medicine group, Ai and hormone medicine group.Ai group and hormone medicine drug dose are respectively 25mg/kg and 5mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 20th day.

Table 5

Group	Hormone medicine	Ai	Tumor control rate (%)	The P value
					1	+	-	60	*
2	-	Sirolimus	46	*
					3	-	Rapamycin	42	*
4	-	Lenalidomide	48	*
					5	-	Ai Sha is for health	36	*
6	+	Sirolimus	80	**
					7	+	Rapamycin	80	**
8	+	Lenalidomide	76	**
					9	+	Ai Sha is for health	76	**

Above result shows, neovascularization inhibitor (Ai) (sirolimus, rapamycin, lenalidomide, Ai Sha are for health) and used hormone medicine (leuprorelin) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.

The tumor-inhibiting action of test 10, Ai and hormone medicine

With the rat is subjects, with 2 * 10 ⁵Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it matched group and treatment group (1-10).The treatment component is Ai group, hormone medicine group, Ai and hormone medicine group.Ai group and hormone medicine drug dose are respectively 15mg/kg and 15mg/kg, through intratumor injection.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 6) on the 20th day.

Table 6

Group	Hormone medicine	Ai	Tumor control rate (%)	The P value
					1	+	-	56	*
2	-	Votaranib	44	*
					3	-	Endostatin	42	*
4	-	Imatinib	38	*
					5	-	Sugen 5416	48	*
6	-	BMS 354825	36	*
					7	+	Votaranib	82	**
8	+	Endostatin	74	**
					9	+	Imatinib	78	**
10	+	Sugen 5416	78	**
					11	+	BMS 354825	84	**

Above result shows, neovascularization inhibitor (Ai) (votaranib, Endostatin, imatinib, Sugen 5416, BMS 354825) and used hormone medicine (leuprorelin) all have significant inhibitory effect (*: the P value is less than 0.05) to tumor growth when this concentration is used separately, can show the potentiation (* *: the P value is less than 0.001) of highly significant when use in conjunction.

The above results shows that when use in conjunction, the weight ratio of Ai and hormone medicine is 1-9: 1 to 1: 1-9, with 1-4: 1 and 4-1: 1 serves as preferred, 1-2: 1 and 2-1: 1 for most preferably.

Studies show that further hormone medicine such as music score of Chinese operas Rayleigh, tamoxifen and gefitinib or rapamycin share tumors such as cervix uteri tumor, thyroid carcinoma, straight colon cancer, ovarian cancer and have obvious synergistic effect (P＜0.05) equally.

In a word, growth all had the obvious suppression effect to kinds of tumor cells when used Ai and/or various hormone medicine were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is the combination of any one Ai and/or any one hormone medicine.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.

Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.

(4) specific embodiment

Embodiment 1.

With 80,80 and 80mg p (BHET-EOP/TC) (BHET-EOP: TC is 80: 20) copolymer put into first, second and the third three containers respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, add 20mg gefitinib, 20mg music score of Chinese operas Rayleigh, 10mg gefitinib and 10mg music score of Chinese operas Rayleigh respectively, shake up the back again and contain 20% gefitinib, 20% music score of Chinese operas Rayleigh, and the injectable microsphere of 10% gefitinib and 10% music score of Chinese operas Rayleigh with spray drying method for preparation.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-50 days, is more than 50 days at the drug release time of the subcutaneous hepatocarcinoma of mice.

Embodiment 2.

The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that used adjuvant is 50: 50 p (BHET-EOP/TC), contains anticancer effective component and percentage by weight thereof and is:

(1) gefitinib of 1-40% or rapamycin;

(2) music score of Chinese operas Rayleigh, tamoxifen, toremifene, letrozole, angiostatin, exemestane or the bicalutamide of 1-30%; Or

(3) combination of music score of Chinese operas Rayleigh, tamoxifen, toremifene, letrozole, exemestane or the bicalutamide of the gefitinib of 1-40% or rapamycin and 1-30%.

Embodiment 3.

With 70mg molecular weight peak value is that the p (LAEG-EOP) of 10000-25000 puts into first, second and the third three containers respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in three containers, add 30mg polyenoid rapamycin, 30mg music score of Chinese operas Rayleigh, 20mg rapamycin and 10mg music score of Chinese operas Rayleigh respectively, shake up the back contains 30% rapamycin, 30% music score of Chinese operas Rayleigh, 20% rapamycin and 10% music score of Chinese operas Rayleigh with spray drying method for preparation injectable microsphere again.Dried microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 55-65 days, is about 60 days at the drug release time of mice lung cancer.

Embodiment 4

The method step that is processed into slow releasing injection is identical with embodiment 3, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:

(1) music score of Chinese operas Rayleigh of 5-30%; Or

(2) gefitinib of 5-40% or rapamycin; Or

(3) combination of the music score of Chinese operas Rayleigh of the gefitinib of 5-30% or rapamycin and 5-30%.

Embodiment 5.

With 60mg molecular weight peak value is that the p (DAPG-EOP) of 10000-25000 puts into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 30 milligrams of gefitinibs and 10 milligrams of thalidomide, shake up the back contains 30% gefitinib and 10% thalidomide with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains 15% sorbitol, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 50-55 days, is about 55 days at the drug release time of the subcutaneous gastric cancer of mice.

Embodiment 6.

The method step that is processed into slow releasing injection is identical with embodiment 5, but the molecular weight peak value of different is used adjuvant is 25000-45000, contains anticancer effective component and is:

(1) gefitinib of 5-40%; Or

(2) thalidomide of 1-20%; Or

(3) combination of the thalidomide of the gefitinib of 5-30% and 1-20%.

Embodiment 7.

With 70mg molecular weight peak value is the p (BHDPT-EOP/TC of 10000-25000,80/20) puts into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 25mg Erlotinib and 5mg tamoxifen, shake up the back contains 25% Erlotinib and 5% tamoxifen with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-45 days, is about 50 days at the drug release time of the subcutaneous esophageal carcinoma of mice.

Embodiment 8.

The method step that is processed into slow releasing injection is identical with embodiment 7, but the molecular weight peak value of different is p (BHDPT-EOP/TC) is 40000-65000, and BHDPT-EOP: TC is 50: 50, and contained anticancer effective component is:

(1) tamoxifen of 10-20%;

(2) gefitinib of 10-25% or Erlotinib; Or

(3) combination of the gefitinib of the tamoxifen of 10-20% and 10-25% or Erlotinib.

Embodiment 9.

With 30mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) and 40mg molecular weight peak value is that p (DAPG-EOP) copolymer of 30000-45000 is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 30mg votaranib, 30mg toremifene, 5mg votaranib and 25mg toremifene respectively, shake up the back again and contain 30% votaranib, 30% toremifene, 5% votaranib and 25% toremifene injectable microsphere with spray drying method for preparation.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection.The drug release time of this slow releasing injection in external normal saline is 40-45 days, is about 45 days at the drug release time of mice skin rectal cancer.

Embodiment 10.

The method step that is processed into slow releasing injection is identical with embodiment 9, but different is in the polifeprosan to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 50: 50, and the molecular weight peak value of p (DAPG-EOP) is 40000-65000, and contained anticancer effective component is:

(1) gefitinib of 5-30%;

(2) toremifene of 20-40%;

(3) combination of the toremifene of the gefitinib of 5-20% and 10-40%.

Embodiment 11

With 40mg molecular weight peak value is that (LAEG-EOP) of 20000-45000p and PLA copolymer that 30mg molecular weight peak value is 10000-25000 are put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg WAY-EKB 569 and 20mg goserelin, shake up the back contains 10% WAY-EKB 569 and 20% goserelin with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 40-45 days, is about 45 days at the drug release time of the subcutaneous breast carcinoma of mice.

Embodiment 12

The method step that is processed into sustained-release implant is identical with embodiment 11, but different is used adjuvant contains anticancer effective component to be for the molecular weight peak value is that (LAEG-EOP) and the molecular weight peak value of 40000-65000p is the PLA of 25000-45000:

(1) WAY-EKB 569 of 10-20%; Or

(2) goserelin of 10-20%; Or

(3) combination of the goserelin of the WAY-EKB 569 of 10-20% and 10-20%.

Embodiment 13

With 40mg molecular weight peak value is the polylactic acid (PLGA of 15000-35000,50: 50) and 30 molecular weight peak values be that (LAEG-EOP) of 20000-45000p puts into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg music score of Chinese operas Rayleigh and 20mg Zarnestra, shake up the back contains 10% music score of Chinese operas Rayleigh and 20% Zarnestra with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 50-60 days, is about 60 days at the drug release time of the subcutaneous cancer of pancreas of mice.

Embodiment 14

The method step of processing sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component is:

(1) gefitinib of 10-20% or Zarnestra; Or

(2) music score of Chinese operas Rayleigh, goserelin or the leuprorelin of 10-20%; Or

(3) combination of music score of Chinese operas Rayleigh, goserelin or the leuprorelin of the gefitinib of 10-20% or Zarnestra and 10-20%.

Embodiment 15

The method step that is processed into slow releasing agent is identical with embodiment 1-14, but different is used slow-release auxiliary material is one of following or its combination:

A) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP);

B) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) are the combination of the polyglycolic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 and the copolymer of hydroxyacetic acid (PLGA) with the molecular weight peak value, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;

C) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and of the combination of molecular weight peak value for the polylactic acid (PLA) of 10000-30000,30000-60000,60000-100000 or 100000-150000;

D) combination of p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and polifeprosan, wherein in the polifeprosan to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;

E) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and bis-fatty acid and decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer decanedioic acid) [P (EAD-SA)], poly-(fumaric acid decanedioic acid) [P (FA-SA)], xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer, hyaluronic acid, collagen protein, the combination of gelatin or white tempera;

F) combination of the copolymer of polifeprosan and glycolic and hydroxyacetic acid or polylactic acid.

Embodiment 16.

The method step that is processed into slow releasing injection is identical with embodiment 1-15, but different is used suspending agent is respectively one of following or its combination:

A) 0.5-3.0% carboxymethyl cellulose (sodium);

B) 5-15% mannitol;

C) 5-15% sorbitol;

D) 0.1-1.5% surfactant;

E) 0.1-0.5% polysorbas20.

Embodiment 17

The method step of processing sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component is:

(a) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin or TNP-470;

(b) triptorelin of 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane or bicalutamide; Or

(c) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin, the triptorelin of TNP-470 and 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, the 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, the combination of exemestane or bicalutamide.

Drug release characteristic (table 7) after embodiment 18 more different slow-release auxiliary material and the combination thereof

The method step of processing sustained-release implant is identical with embodiment 11, the drug release characteristic after more different slow-release auxiliary material and the combination thereof.First day release amount of medicine (external) surpass 20% of total amount and release for prominent.

Table 7

Slow-release auxiliary material	Molecular weight	Medicine and content	Drug release time (my god)	Not prominent releasing arranged
					(1) PLA, (2) PLGA, (50/50), (3) Polifeprosan, (20/80), (4) p, (LAEG-EOP), (1):, (4)=1: 1, (2):, (4)=1: 1, (3):, (4)=1: 1, (5) PLA, (6) PLGA, (75/25), (7) Polifeprosan, (50/50), (8) p, (DAPG-EOP), (5):, (8)=6: 4, (6):, (8)=7: 3, (7):, (8)=5: 5	10000-25000 20000-40000 20000-40000 15000-35000 25000-45000 10000-20000 10000-20000 35000-55000	Gefitinib (20%) Gefitinib (20%) Gefitinib (20%) Gefitinib (20%) Gefitinib (20%) Gefitinib (20%) Gefitinib (20%) Leuprorelin (20%) Leuprorelin (20%) Leuprorelin (20%) Leuprorelin (20%) Leuprorelin (20%) Leuprorelin (20%) Leuprorelin (20%)	22 28 10 48 42 44 42 26 25 10 54 50 48 46	Not having to have or not have to have or not does not have

Data show in the table, and when PLA, PLGA (50/50) and polifeprosan sugared acid anhydride family macromolecule polymer such as (20/80) were used separately, drug release was very fast, and wherein the drug release time of polifeprosan is 8-10 days and obviously prominent releasing arranged.P (LAEG-EOP) and p poly phosphate high molecular polymer releases such as (DAPG-EOP) are slow and steady, can alleviate caused prominent the releasing of the latter when share with sugared acid anhydride family macromolecule polymer such as PLA, PLGA, polifeprosans, but its steadily slowly drug release feature be not subjected to too big influence.This beyond thought discovery constitutes another major technique feature of the present invention.Because the poly phosphate high molecular polymer costs an arm and a leg, this will help reducing the cost of slow releasing preparation, and improve its drug release feature.

Drug release characteristic (table 8) after embodiment 19 more different slow-release auxiliary material and the combination thereof

The method step of processing sustained-release implant is identical with embodiment 11, the drug release characteristic after more different slow-release auxiliary material and the combination thereof.First day release amount of medicine (external) surpass 20% of total amount and release for prominent.

Table 8

Slow-release auxiliary material	Molecular weight	Medicine and content	Drug release time (my god)	Not prominent releasing arranged
					(1) PLA, (2) PLGA, (50/50), (3) Polifeprosan, (20/80), (4) p, (LAEG-EOP), (1):, (4)=1: 1, (2):, (4)=1: 1, (3):, (4)=1: 1, (5) PLA, (6) PLGA, (75/25), (7) Polifeprosan, (50/50), (8) p, (DAPG-EOP), (5):, (8)=6: 4, (6):, (8)=7: 3, (7):, (8)=5: 5	20000-35000 30000-45000 20000-40000 25000-45000 25000-45000 20000-40000 20000-40000 35000-55000	Music score of Chinese operas Rayleigh, music score of Chinese operas Rayleigh, music score of Chinese operas Rayleigh, music score of Chinese operas Rayleigh, music score of Chinese operas Rayleigh, music score of Chinese operas Rayleigh, rapamycin (20%) rapamycin (20%) rapamycin (20%) rapamycin (20%) rapamycin (20%) rapamycin (20%) rapamycin (20%) music score of Chinese operas Rayleigh (10%) (10%) (10%) (10%) (10%) (10%) (10%)	25 32 11 48 43 45 42 27 25 13 57 55 52 50	Not having to have or not have to have or not does not have

Data show in the table, and when PLA, PLGA (50/50) and polifeprosan sugared acid anhydride family macromolecule polymer such as (20/80) were used separately, drug release was very fast, and wherein the drug release time of polifeprosan is 10-13 days and obviously prominent releasing arranged.P (LAEG-EOP) and p poly phosphate high molecular polymer releases such as (DAPG-EOP) are slow and steady, can alleviate caused prominent the releasing of the latter when share with sugared acid anhydride family macromolecule polymer such as PLA, PLGA, polifeprosans, but its steadily slowly drug release feature be not subjected to too big influence.This beyond thought discovery constitutes another major technique feature of the present invention.Because the poly phosphate high molecular polymer costs an arm and a leg, this will help reducing the cost of slow releasing preparation, and improve its drug release feature.

This release rule also sees to the other drug combination, as the combination of leuprorelin and gefitinib and the combination of WAY-EKB 569 or thalidomide and tamoxifen.

Above embodiment only is used for explanation, and is not limitation application of the present invention.

The present invention disclosed and the protection the content see claim.

Claims (10)

1. anti-cancer composition that contains neovascularization inhibitor and hormone medicine is characterized in that anti-cancer composition is a slow releasing injection, is grouped into by following one-tenth:

(A) sustained-release micro-spheres comprises:

Anticancer effective component 0.5-70%

Slow-release auxiliary material 30-99%

Suspending agent 0.0-30%

More than be weight percentage

With

(B) solvent is for common solvent or contain the special solvent of suspending agent.

Wherein,

Anticancer effective component is neovascularization inhibitor and/or hormone medicine;

Slow-release auxiliary material is selected from mixing or copolymer of phosphate ester high molecular polymer or phosphate ester high molecular polymer and dextranomer family macromolecule polymer:

Neovascularization inhibitor is selected from ZD6474, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin or TNP-470;

The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), is selected from one of sodium carboxymethyl cellulose, iodine glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.

2. the anti-cancer composition according to claim 1, it is characterized in that hormone medicine be selected from triptorelin, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen, not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane or bicalutamide.

3. the anti-cancer composition according to claim 1 is characterized in that the anticancer effective component of slow-releasing anticarcinogen injection is:

(a) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin or TNP-470;

(b) triptorelin of 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane or bicalutamide; Or

(c) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin, the triptorelin of TNP-470 and 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, the 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, the combination of exemestane or bicalutamide.

Below all be weight percentage.

Slow-release auxiliary material is one of following or its combination:

A) poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester), poly-(L-lactide-co-etherophosphoric acid, poly-(L-lactide-co-phosphoric acid propyl ester), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride), poly-(anti-(formula)-1,4-dimethyl cyclohexane etherophosphoric acid) or poly-(anti-(formula)-1,4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP));

B) poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester), poly-(L-lactide-co-etherophosphoric acid, poly-(L-lactide-co-phosphoric acid propyl ester), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) or poly-(anti-(formula)-1, the combination of the copolymer of 4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)) and polyglycolic acid and hydroxyacetic acid, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;

C) poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester), poly-(L-lactide-co-etherophosphoric acid, poly-(L-lactide-co-phosphoric acid propyl ester), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) or poly-(anti-(formula)-1, the combination of 4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)) and polylactic acid;

D) poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester), poly-(L-lactide-co-etherophosphoric acid, poly-(L-lactide-co-phosphoric acid propyl ester), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) or poly-(anti-(formula)-1, the combination of 4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)) and polifeprosan, wherein in the polifeprosan to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40; Or

E) poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-etherophosphoric acid/terephthalic acids ester hydrochloride ester), poly-(L-lactide-co-etherophosphoric acid, poly-(L-lactide-co-phosphoric acid propyl ester), poly-(1,4-two (hydroxyl ethyl ester) terephthalate-co-4-dimethylamino pyridine-co-etherophosphoric acid/terephthalic acids ester hydrochloride), poly-(anti-(formula)-1,4-dimethyl cyclohexane-etherophosphoric acid) or poly-(anti-(formula)-1,4-dimethyl cyclohexane-hexyl dichloro-phosphate ester (p (CHDM-EOP)) and bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer, hyaluronic acid, collagen protein, the combination of gelatin or white tempera;

F) combination of the copolymer of polifeprosan and glycolic and hydroxyacetic acid or polylactic acid.

4. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that used suspending agent is respectively one of following or its combination:

A) 0.5-3.0% carboxymethyl cellulose (sodium);

B) 5-15% mannitol;

C) 5-15% sorbitol;

D) 0.1-1.5% surfactant;

E) 0.1-0.5% polysorbas20; Or

F) glycerol, simethicone, propylene glycol or carbomer.

5. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that used suspending agent is one of following:

A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80;

B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or

C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.

6. be sustained-release implant according to the described anti-cancer composition of claim 1.

7. the anti-cancer sustained-released implantation agent according to claim 6 is characterized in that anticancer effective component is:

(a) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin or TNP-470;

(b) triptorelin of 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, exemestane or bicalutamide; Or

(c) ZD6474 of 1-40%, Zarnestra, sirolimus, rapamycin, lenalidomide, Ai Sha is for health, gefitinib, Erlotinib, Lapatinib, votaranib, WAY-EKB 569, NSC 609974, thalidomide, LS-2616, angiostatin, Endostatin, the blood vessel endothelium chalone, the grace degree, imatinib mesylate, Sugen 5416, BMS 354825, Avastin, Cl 1033, Sorafenib, Sutent, TLK286, ABX-EGF, Marimastat, SU5416, SU6668, Amebacilin, the triptorelin of TNP-470 and 1-40%, goserelin, leuprorelin, Anastrozole, idoxifene, Miproxifene, tamoxifen, 4-monohydroxy tamoxifen (OH-TAM), not former times sweet smell, raloxifene, ICI-M 164384, anticancer steroid alkene phenol, the 4-trans-Hydroxytamoxifen, Drogenil, aminoglutethimide, (.+-.)-Pyridoglutethimide, megestrol, medroxyprogesterone, clomifene, toremifene, letrozole, Anastrozole, the combination of exemestane or bicalutamide.

Slow-release auxiliary material is selected from mixing or copolymer of phosphate ester high molecular polymer or phosphate ester high molecular polymer and dextranomer family macromolecule polymer.

8. the described anti-cancer sustained-released implantation agent according to claim 6, it is one of following to it is characterized in that slow-release auxiliary material is selected from:

A) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP);

B) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and molecular weight peak value are the combination of the copolymer of the polyglycolic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 and hydroxyacetic acid, wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50;

C) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) are the combination of the polylactic acid of 10000-30000,30000-60000,60000-100000 or 100000-150000 with the molecular weight peak value;

D) combination of p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and polifeprosan, wherein in the polifeprosan to carboxy phenyl propane: the certain herbaceous plants with big flowers diacid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;

E) p (BHET-EOP/TC), p (BHET-EOP/TC), p (LAEG-EOP), p (DAPG-EOP), p (BHDPT-EOP/TC), p (BHDPT-EOP/TC), p (CHDM-HOP) or p (CHDM-EOP) and bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), xylitol, oligosaccharide, chrondroitin, chitin, chitosan, poloxamer, hyaluronic acid, collagen protein, gelatin or the combination of tempera in vain;

F) combination of the copolymer of polifeprosan and glycolic and hydroxyacetic acid or polylactic acid.

9. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that effective ingredient in the slow-releasing anticarcinogen injection is used to prepare the pharmaceutical preparation that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.

10. according to claim 1 and 6 described slow-releasing anticarcinogen injection and slow releasing injection, it is characterized in that anticancer sustained-release agent in tumor or tumor week injection or place administration, in sustained release profile in vivo test more than 40 days.